QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=85F3AD31C3DFC248238A1727A44AF69B;jsessionid=8F66B3985AC39B171802D43D3ABBA47B;jsessionid=EC398BED0811BC6736D6C5AB9CA79F0F;jsessionid=05EDA3A1FA65ACA3F6F94A8B22864ABF;jsessionid=433BFDC5791C260D6AF588BB35B016D9;jsessionid=82F5EBF3B7A7D65FFA3B6460B3893C00;jsessionid=22E8DC715B406C3CEDEF513BA26AADF3 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=85F3AD31C3DFC248238A1727A44AF69B;jsessionid=8F66B3985AC39B171802D43D3ABBA47B;jsessionid=EC398BED0811BC6736D6C5AB9CA79F0F;jsessionid=05EDA3A1FA65ACA3F6F94A8B22864ABF;jsessionid=433BFDC5791C260D6AF588BB35B016D9;jsessionid=82F5EBF3B7A7D65FFA3B6460B3893C00;jsessionid=22E8DC715B406C3CEDEF513BA26AADF3